|
|
HIV Update 2002 (6): JunePublished by: Datamonitor Published: Oct. 3, 2002 - 25 Pages Table of ContentsOverview Introduction June 2002 was an important month in the HIV market. Pricing pressure for HIV therapies continued to intensify in the US market, with a major competitor reprimanded for its pricing policy. The shift towards more fully recognising side-effect profiles within treatment decisions continues, with clinical trial data being published highlighting the importance of toxicity in maximising HIV patients' QOL. Scope Datamonitor has provided a descriptive analysis of each of the key events, commenting as to their likely market impact. This Brief summarises the key events and developments that have taken place in the HIV market during June 2002. Report Highlights Historically, the level of unmet need in the HIV market has meant that premuim pricing strategies for new HIV products have been undertaken. However, the increasing predominance of patient advocacy groups and awareness of healthcare payors over the cost of HIV therapy is placing pressure on such pricing strategies. Organisations such as Aids Healthcare Foundation in the US are now seeking to restrict HIV sales force promotion activities on the basis of price. Reasons to Purchase Keep track of all of the important events taking place in the HIV market, with comprehensive coverage of key clinical trial data and product news. Gain insight into the likey market impact of the events that took place in June in the HIV market. DRIVERS AND TRENDS The HIV pharmaceutical industry may start to face a changing trend with increasing pressure from the developed world to cut prices of anti-retroviral drugs. This is partly in response to overpricing of current drug, but also an attempt to match price cuts in the developing world. Not only is price an issue, but also side effects associated with currently marketed drugs. Much more emphasis is being placed on quality of life issues, with patients skipping doses if therapy becomes too hard to endure. Consequently, much clinical research is being concentrated on attempting to reduce drug-associated co-morbidities. Current treatment strategies revolve around drugs that combat the virus after it has infected an individual. Less emphasis is being placed on preventing infection. Determining alternative avenues of combating HIV is at the forefront of both patients and physicians minds. COMPANY HEADLINES A summary of the latest events from a company perspective Anadys and Gilead Form Collaboration to Discover New Antiviral Compounds GlaxoSmithKline Taken to Court Over Drug Pricing Co-Distribution of Rapid HIV Kit: Agreement Between OraSure and Abbott RESEARCH AND DEVELOPMENT HEADLINES A summary of the key events from a clinical and pipeline drug perspective Lipodystrophy Uncommon in Children taking HAART Poor response to HAART may Boost Antifungal Sales Ritonavir Could Combat Kaposi’s New York AIDS Patients Given Glimmer of Hope Ethnicity May Affect Side Effect Risks from HAART Trials show Viread Effective in Treatment Experienced Patients Limited HAART Risk During Pregnancy Mortality and Pain Linked in HAART Treated HIV Infected Children Mortality and Pain Linked in HAART Treated HIV Infected Children Lopinavir Ritonavir Combination Proves Potent Late Stage Symptoms Can Appear in Recently Infected HIV Patients DISEASE SPECIFIC HEADLINES An overview of the epidemiological and research perspective T-Cell Repopulation Following HAART Linked to Thymus Catabolic Cytokines Blamed for Loss of Lean Body Mass in HIV Stem Cell Potential for HIV patient Immune Reconstitution Gene Variation Ruled Out in HAART Complications Monocytes Contribute to CD4 T-cell Apoptosis EMERGING MARKETS HEADLINES A summary of the key events from the emerging markets HIV Subtype Differences May Not Affect Response to HAART Heroin Use Related to Rise in HIV Incidence AbstractIntroduction: June 2002 was an important month in the HIV market. Pricing pressure for HIV therapies continued to intensify in the US market, with a major competitor reprimanded for its pricing policy. The shift towards more fully recognizing side-effect profiles within treatment decisions continues, with clinical trial data being published highlighting the importance of toxicity in maximizing HIV patients' QOL. Scope of the Report: * Datamonitor has provided a descriptive analysis of each of the key events, commenting as to their likely market impact. * This Brief summarizes the key events and developments that have taken place in the HIV market during June 2002. Report Highlights: Historically, the level of unmet need in the HIV market has meant that premium pricing strategies for new HIV products have been undertaken. However, the increasing predominance of patient advocacy groups and awareness of healthcare payers over the cost of HIV therapy is placing pressure on such pricing strategies. Organizations such as AIDS Healthcare Foundation in the US are now seeking to restrict HIV sales force promotion activities on the basis of price. Key Reasons to Buy this Report: * Keep track of all of the important events taking place in the HIV market, with comprehensive coverage of key clinical trial data and product news. * Gain insight into the likely market impact of the events that took place in June 2002 in the HIV market.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||